Content for healthcare professionals only

View all Platforms Cardiology

Topics Content Type Videos Articles Journals Broadcasts Education Podcasts News Journals AER CFR ECR ICR3 JAPSC USC Faculty Events Upcoming Events Radcliffe Events All Events Resource Hubs Empagliflozin in the Treatment of Chronic Heart Failure Pulmonary Embolism Pulsed Field Ablation

Radcliffe Platforms

Radcliffe Group Cardiology Vascular CVRM Medical Education

Content for healthcare professionals only

Content Type

Events

Resource Hubs

AHA Scientific Sessions 2024 Late-Breaking and Featured Science Collection

Published: 29 October 2024

Views:
2109
Likes:
7

Views:
2109
Likes:
7
Share:

Now Playing
Part 3 | Session 14 of 14
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation
Oussama M Wazni

Up Next

10m 27s

Part 4 3 Trials That Will Change My Practice with Dr Michelle Kittleson
Michelle Kittleson

13m 43s

Part 1 View from the Thoraxcenter: AHA 24 Late-breaking Preview Joost Daemen, Nicolas M Van Mieghem

29m 32s

Part 2 | Session 1 ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS Harriette Van Spall, Kausik Ray

18m 41s

Part 2 | Session 2 NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI Harriette Van Spall, Tor Biering-Sørensen

17m 22s

Part 2 | Session 3 SUMMIT: Tirzepatide in Patients with HFpEF and Obesity Harriette Van Spall, Milton Packer

16m 57s

Part 2 | Session 4 FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk Harriette Van Spall, Katherine Tuttle

22m 30s

Part 2 | Session 5 REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone Harriette Van Spall, Mikhail Kosiborod

6m 17s

Part 3 | Session 1 LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD Dean J Kereiakes

3m 53s

Part 3 | Session 2 LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia Frederick Raal

7m 19s

Part 3 | Session 3 Mavacamten: Real-World Experience from 22 Months of the REMS Program Milind Y Desai

10m 31s

Part 3 | Session 4 VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy Milind Y Desai

4m 41s

Part 3 | Session 5 EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure Andrew JS Coats

6m 53s

Part 3 | Session 6 Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results Dhanunjaya Lakkireddy

5m 6s

Part 3 | Session 7 NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy Marianna Fontana

5m 7s

Part 3 | Session 8 SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery Subodh Verma

4m 30s

Part 3 | Session 9 ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF Sanjiv Shah

3m 49s

Part 3 | Session 10 New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD Marc P Bonaca

5m 28s

Part 3 | Session 11 ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients Steven E Nissen

3m 44s

Part 3 | Session 12 BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH Stephen Nicholls

3m 40s

Part 3 | Session 13 KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients Stephen Nicholls

Average (ratings)

No ratings

Your rating

Overview

Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.

To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL).
Watch out for the Late-Breaker Discussions with Dr Harriette Van Spall for key clinical trial data and its implications for future research.
Our concise Expert Interviews provide key data, study designs and take-home messages from select faculty.
Don't miss the key take aways from our Highlights series.

More from this programme

Part 1

View From the Thoraxcenter

1 session
View from the Thoraxcenter: AHA 24 Late-breaking Preview	Watch now

Part 2

Late-Breaker Discussions with Dr Harriette Van Spall

5 sessions
ZODIAC: Decision Support System to Aid Optimization of Early Lipid Lowering Therapies After ACS	Watch now
NUDGE-FLU: Electronic Nudges to Increase Influenza Vaccination in Patients with MI	Watch now
SUMMIT: Tirzepatide in Patients with HFpEF and Obesity	Watch now
FLOW: Benefits of Semaglutide on CKD by Cardiovascular Status or Risk	Watch now
REALIZE-K: Efficacy and Safety of SZC in Patients with HFrEF Receiving Spironolactone	Watch now

Part 3

Expert Interviews

14 sessions
LIBerate-OLE: Long-Term Efficacy of Lerodalcibep in Patients at High Risk for CVD	Watch now
LIBerate-HeFH_OLE: Lerodalcibep in Heterozygous Familial Hypercholesterolemia	Watch now
Mavacamten: Real-World Experience from 22 Months of the REMS Program	Watch now
VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy	Watch now
EMPEROR-Preserved: Diastolic Dysfunction and Empagliflozin in Heart Failure	Watch now
Amulet IDE: The AMPLATZER Amulet Left Atrial Appendage Occluder Five-Year Results	Watch now
NTLA-2001 in Patients with Transthyretin Amyloidosis with Cardiomyopathy	Watch now
SELECT: Semaglutide in Obese and Overweight Patients with a History of Coronary Artery Bypass Surgery	Watch now
ENDEAVOR: Myeloperoxidase Inhibition with Mitiperstat in HFpEF	Watch now
New Insights from CLEAR OUTCOMES: Bempedoic Acid in Statin-Intolerant Patients with PAD	Watch now
ALPACAR: Phase 2 Trial of Zerlasiran in High Risk Patients	Watch now
BROOKLYN: Safety and Efficacy of Obicetrapib in Patients with HeFH	Watch now
KRAKEN: Phase 2 Trial of Muvalaplin in High Risk Patients	Watch now
OPTION: LAA Closure with Oral Anticoagulation after AF Ablation	Watch now

Part 4

Highlights

1 session
3 Trials That Will Change My Practice with Dr Michelle Kittleson	Watch now

About the episode

AHA Conference 2024 - Safety and efficacy outcomes comparing left atrial appendage (LAA) closure with the WATCHMAN FLX device to oral anticoagulation (OAC) following atrial fibrillation (AF) catheter ablation.

Dr Oussama Wazni (The Cleveland Clinic Foundation, Ohio, US) joins us onsite at AHA Conference to discuss the findings from OPTION (NCT03795298).

OPTION is a prospective, multi-center, multi-national trial where patients with moderate to high risk of stroke who received AF catheter ablation were randomized to receive either LAA with the WATCHMAN FLX device or market-approved OAC. 1,600 patients were enrolled and were followed up through 36 months. The primary effectiveness endpoint is stroke, all cause death, systemic embolism, and the primary safety endpoint is non-procedural bleeding.

Interview Questions:
1.    What is the reasoning behind the OPTION trial?
2.    What is the current research landscape for LAA closure following AF ablation?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area, and what are the next steps?

Recorded remotely from Ohio, 2024.

Editors: Yazmin Sadik, Jordan Rance.
Videographers: David Ben-Harosh.

Support: This is an independent interview produced by Arrhythmia Academy.

Faculty Biographies

Oussama M Wazni

Oussama M Wazni

Cleveland Clinic, US

View full profile

Comments

You must be to comment. If you are not registered, you can register here.